WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said a newly published systematic review strengthens the scientific case for using topical statins to treat porokeratosis, a rare and progressive ...
A recent study has carried out a systematic review of the scientific literature on omics data generated in pituitary tumors, with the aim of organizing, cataloging and facilitating the reuse of ...
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis ...
This systematic review and meta-analysis identified prognostic factors associated with early mortality in septic shock. The identification of these prognostic factors could aid in clinical risk ...
An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will evaluate the current standards for high-quality systematic reviews for comparative effectiveness research and ...
A recent study has carried out a systematic review of the scientific literature on omics data generated in pituitary tumours, ...
Investing.com -- Palvella Therapeutics Inc (NASDAQ:PVLA) stock gained 5.6% Monday following the publication of a systematic review in Clinical and Experimental Dermatology supporting the scientific ...
Objectives Maternal dietary practices are vital for improving maternal and neonatal outcomes. However, comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results